

**Clinical trial results:****A Randomized, Open-Label Study to Evaluate the Safety and Efficacy of the Co-Administration of Ombitasvir/ABT-450/Ritonavir (Ombitasvir/ABT-450/r) With Sofosbuvir (SOF) With or Without Ribavirin (RBV) in Subjects With Genotype 2 Chronic Hepatitis C Virus (HCV) Infection or Genotype 3 HCV Infection With or Without Cirrhosis.****Summary**

EudraCT number	2014-003147-35
Trial protocol	GB
Global end of trial date	14 July 2017

Results information

Result version number	v1 (current)
This version publication date	12 July 2018
First version publication date	12 July 2018

Trial information**Trial identification**

Sponsor protocol code	M14-567
-----------------------	---------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT02292719
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	AbbVie Deutschland GmbH & Co. KG
Sponsor organisation address	AbbVie House, Vanwall Business Park, Vanwall Road, Maidenhead, Berkshire, United Kingdom, SL6-4UB
Public contact	Global Medical Services, AbbVie, 001 800-633-9110, eu-clinical-trials@abbvie.com
Scientific contact	Mariem Charafeddine, AbbVie, mariem.charafeddine@abbvie.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	14 July 2017
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	14 July 2017
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

The purpose of this study is to evaluate the safety and efficacy of Ombitasvir (OBV)/paritaprevir (PTV)/ritonavir (r) with sofosbuvir (SOF) with or without ribavirin (RBV) in adults with Genotype 2 Chronic Hepatitis C Virus (HCV) infection or Genotype 3 HCV infection with or without Cirrhosis.

Protection of trial subjects:

Prior to the initiation of any screening or study-specific procedures, the investigator or his or her representative explained the nature of the study to the subject or his or her representative and answered all questions regarding this study.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	19 December 2014
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Australia: 19
Country: Number of subjects enrolled	New Zealand: 13
Country: Number of subjects enrolled	Canada: 22
Country: Number of subjects enrolled	United Kingdom: 16
Worldwide total number of subjects	70
EEA total number of subjects	16

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	66

From 65 to 84 years	4
85 years and over	0

Subject disposition

Recruitment

Recruitment details:

All subjects who received at least 1 dose of study drug were included in the intent-to-treat (ITT) population; the safety population is the same as the ITT population.

Pre-assignment

Screening details:

The study included a 35-day screening period.

Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Not blinded

Arms

Are arms mutually exclusive?	Yes
Arm title	Arm A (genotype [GT]3, noncirrhotic)

Arm description:

Ombitasvir (OBV)/paritaprevir (PTV)/ritonavir (r) 25/150/100 mg once daily (QD) and sofosbuvir (SOF) 400 mg QD for 12 weeks.

Arm type	Experimental
Investigational medicinal product name	Sofosbuvir
Investigational medicinal product code	
Other name	Sovaldi
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Sofosbuvir (SOF) 400 mg QD for 12 weeks

Investigational medicinal product name	Ombitasvir/paritaprevir/ritonavir
Investigational medicinal product code	
Other name	ABT-267 also known as ombitasvir, ABT-450 also known as paritaprevir, ritonavir also known as Norvir, VIEKIRAX combination tablets, TECHNIVIE
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Ombitasvir (OBV)/paritaprevir (PTV)/ritonavir (r) 25/150/100 mg once daily (QD) for 12 weeks.

Arm title	Arm B (GT3, noncirrhotic)
------------------	---------------------------

Arm description:

Ombitasvir (OBV)/paritaprevir (PTV)/ritonavir (r) (25/150/100) mg QD with sofosbuvir (SOF) (400 mg QD) and ribavirin (RBV; weight-based 1,000 mg or 1,200 mg daily divided twice daily [BID]) for 12 weeks.

Arm type	Experimental
Investigational medicinal product name	Ombitasvir/paritaprevir/ritonavir
Investigational medicinal product code	
Other name	ABT-267 also known as ombitasvir, ABT-450 also known as paritaprevir, ritonavir also known as Norvir, VIEKIRAX combination tablets, TECHNIVIE
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details: Ombitasvir (OBV)/paritaprevir (PTV)/ritonavir (r) 25/150/100 mg once daily (QD) for 12 weeks.	
Investigational medicinal product name	Ribavirin (RBV)
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use
Dosage and administration details: RBV weight-based 1,000 mg or 1,200 mg daily divided twice daily [BID] for 12 weeks.	
Investigational medicinal product name	Sofosbuvir
Investigational medicinal product code	
Other name	Sovaldi
Pharmaceutical forms	Tablet
Routes of administration	Oral use
Dosage and administration details: Sofosbuvir 400 mg QD for 12 weeks.	
Arm title	Arm C (GT2, Noncirrhotic)
Arm description: Ombitasvir (OBV)/paritaprevir (PTV)/ritonavir (r) (25/150/100) mg QD with sofosbuvir (SOF) (400 mg QD) and ribavirin (RBV; weight- based 1,000 mg or 1,200 mg daily divided BID) for 8 weeks.	
Arm type	Experimental
Investigational medicinal product name	Ombitasvir/paritaprevir/ritonavir
Investigational medicinal product code	
Other name	ABT-267 also known as ombitasvir, ABT-450 also known as paritaprevir, ritonavir also known as Norvir, VIEKIRAX combination tablets, TECHNIVIE
Pharmaceutical forms	Tablet
Routes of administration	Oral use
Dosage and administration details: Ombitasvir (OBV)/paritaprevir (PTV)/ritonavir (r) 25/150/100 mg once daily (QD) for 8 weeks.	
Investigational medicinal product name	Ribavirin (RBV)
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use
Dosage and administration details: RBV weight- based 1,000 mg or 1,200 mg daily divided BID for 8 weeks.	
Investigational medicinal product name	Sofosbuvir
Investigational medicinal product code	
Other name	Sovaldi
Pharmaceutical forms	Tablet
Routes of administration	Oral use
Dosage and administration details: Sofosbuvir 400 mg QD for 8 weeks.	
Arm title	Arm D (GT2, Noncirrhotic)
Arm description: Ombitasvir (OBV)/paritaprevir (PTV)/ritonavir (r) (25/150/100) mg QD with sofosbuvir (SOF) (400 mg QD) and ribavirin (RBV; weight-based 1,000 mg or 1,200 mg daily divided BID) for 6 weeks.	
Arm type	Experimental

Investigational medicinal product name	Ombitasvir/paritaprevir/ritonavir
Investigational medicinal product code	
Other name	ABT-267 also known as ombitasvir, ABT-450 also known as paritaprevir, ritonavir also known as Norvir, VIEKIRAX combination tablets, TECHNIVIE
Pharmaceutical forms	Tablet
Routes of administration	Oral use
Dosage and administration details: Ombitasvir (OBV)/paritaprevir (PTV)/ritonavir (r) 25/150/100 mg once daily (QD) for 6 weeks.	
Investigational medicinal product name	Ribavirin (RBV)
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use
Dosage and administration details: RBV weight- based 1,000 mg or 1,200 mg daily divided BID for 6 weeks.	
Investigational medicinal product name	Sofosbuvir (SOF)
Investigational medicinal product code	
Other name	Sovaldi
Pharmaceutical forms	Tablet
Routes of administration	Oral use
Dosage and administration details: SOF 400 mg QD for 6 weeks	
Arm title	Arm E (GT3, Cirrhotic)
Arm description: Ombitasvir (OBV)/paritaprevir (PTV)/ritonavir (r) (25/150/100) mg QD with sofosbuvir (SOF) (400 mg QD) and ribavirin (RBV; weight-based 1,000 mg or 1,200 mg daily divided BID) for 12 weeks.	
Arm type	Experimental
Investigational medicinal product name	Ombitasvir/paritaprevir/ritonavir
Investigational medicinal product code	
Other name	ABT-267 also known as ombitasvir, ABT-450 also known as paritaprevir, ritonavir also known as Norvir, VIEKIRAX combination tablets, TECHNIVIE
Pharmaceutical forms	Tablet
Routes of administration	Oral use
Dosage and administration details: Ombitasvir (OBV)/paritaprevir (PTV)/ritonavir (r) 25/150/100 mg once daily (QD) for 12 weeks.	
Investigational medicinal product name	Ribavirin (RBV)
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use
Dosage and administration details: RBV weight-based 1,000 mg or 1,200 mg daily divided twice daily [BID] for 12 weeks.	
Investigational medicinal product name	Sofosbuvir
Investigational medicinal product code	
Other name	Sovaldi
Pharmaceutical forms	Tablet
Routes of administration	Oral use
Dosage and administration details: Sofosbuvir 400 mg QD for 12 weeks.	
Arm title	Arm F (GT3, Noncirrhotic)

Arm description:

Ombitasvir (OBV)/paritaprevir (PTV)/ritonavir (r) (25/150/100) mg QD and Sofosbuvir (SOF) (400 mg QD) for 12 weeks.

Arm type	Experimental
Investigational medicinal product name	Ombitasvir/paritaprevir/ritonavir
Investigational medicinal product code	
Other name	ABT-267 also known as ombitasvir, ABT-450 also known as paritaprevir, ritonavir also known as Norvir, VIEKIRAX combination tablets, TECHNIVIE
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Ombitasvir (OBV)/paritaprevir (PTV)/ritonavir (r) 25/150/100 mg once daily (QD) for 12 weeks.

Investigational medicinal product name	Sofosbuvir
Investigational medicinal product code	
Other name	Sovaldi
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Sofosbuvir (SOF) 400 mg QD for 12 weeks

Number of subjects in period 1	Arm A (genotype [GT]3, noncirrhotic)	Arm B (GT3, noncirrhotic)	Arm C (GT2, Noncirrhotic)
Started	9	11	10
Completed	9	11	9
Not completed	0	0	1
Consent withdrawn by subject	-	-	-
Subject enrolled in new study.	-	-	1

Number of subjects in period 1	Arm D (GT2, Noncirrhotic)	Arm E (GT3, Cirrhotic)	Arm F (GT3, Noncirrhotic)
Started	9	21	10
Completed	8	20	10
Not completed	1	1	0
Consent withdrawn by subject	1	1	-
Subject enrolled in new study.	-	-	-

Baseline characteristics

Reporting groups

Reporting group title	Arm A (genotype [GT]3, noncirrhotic)
-----------------------	--------------------------------------

Reporting group description:

Ombitasvir (OBV)/paritaprevir (PTV)/ritonavir (r) 25/150/100 mg once daily (QD) and sofosbuvir (SOF) 400 mg QD for 12 weeks.

Reporting group title	Arm B (GT3, noncirrhotic)
-----------------------	---------------------------

Reporting group description:

Ombitasvir (OBV)/paritaprevir (PTV)/ritonavir (r) (25/150/100) mg QD with sofosbuvir (SOF) (400 mg QD) and ribavirin (RBV; weight-based 1,000 mg or 1,200 mg daily divided twice daily [BID]) for 12 weeks.

Reporting group title	Arm C (GT2, Noncirrhotic)
-----------------------	---------------------------

Reporting group description:

Ombitasvir (OBV)/paritaprevir (PTV)/ritonavir (r) (25/150/100) mg QD with sofosbuvir (SOF) (400 mg QD) and ribavirin (RBV; weight-based 1,000 mg or 1,200 mg daily divided BID) for 8 weeks.

Reporting group title	Arm D (GT2, Noncirrhotic)
-----------------------	---------------------------

Reporting group description:

Ombitasvir (OBV)/paritaprevir (PTV)/ritonavir (r) (25/150/100) mg QD with sofosbuvir (SOF) (400 mg QD) and ribavirin (RBV; weight-based 1,000 mg or 1,200 mg daily divided BID) for 6 weeks.

Reporting group title	Arm E (GT3, Cirrhotic)
-----------------------	------------------------

Reporting group description:

Ombitasvir (OBV)/paritaprevir (PTV)/ritonavir (r) (25/150/100) mg QD with sofosbuvir (SOF) (400 mg QD) and ribavirin (RBV; weight-based 1,000 mg or 1,200 mg daily divided BID) for 12 weeks.

Reporting group title	Arm F (GT3, Noncirrhotic)
-----------------------	---------------------------

Reporting group description:

Ombitasvir (OBV)/paritaprevir (PTV)/ritonavir (r) (25/150/100) mg QD and Sofosbuvir (SOF) (400 mg QD) for 12 weeks.

Reporting group values	Arm A (genotype [GT]3, noncirrhotic)	Arm B (GT3, noncirrhotic)	Arm C (GT2, Noncirrhotic)
Number of subjects	9	11	10
Age categorical Units: Subjects			

Age continuous Units: years arithmetic mean standard deviation	52.1 ± 9.17	53.5 ± 8.26	56.6 ± 6.70
Gender categorical Units: Subjects			
Female	4	4	5
Male	5	7	5

Reporting group values	Arm D (GT2, Noncirrhotic)	Arm E (GT3, Cirrhotic)	Arm F (GT3, Noncirrhotic)
Number of subjects	9	21	10
Age categorical Units: Subjects			

Age continuous Units: years arithmetic mean standard deviation	61.6 ± 5.90	53.8 ± 6.56	48.9 ± 7.52
Gender categorical Units: Subjects			
Female	3	9	2
Male	6	12	8

Reporting group values	Total		
Number of subjects	70		
Age categorical Units: Subjects			

Age continuous Units: years arithmetic mean standard deviation	-		
Gender categorical Units: Subjects			
Female	27		
Male	43		

End points

End points reporting groups

Reporting group title	Arm A (genotype [GT]3, noncirrhotic)
Reporting group description: Ombitasvir (OBV)/paritaprevir (PTV)/ritonavir (r) 25/150/100 mg once daily (QD) and sofosbuvir (SOF) 400 mg QD for 12 weeks.	
Reporting group title	Arm B (GT3, noncirrhotic)
Reporting group description: Ombitasvir (OBV)/paritaprevir (PTV)/ritonavir (r) (25/150/100) mg QD with sofosbuvir (SOF) (400 mg QD) and ribavirin (RBV; weight-based 1,000 mg or 1,200 mg daily divided twice daily [BID]) for 12 weeks.	
Reporting group title	Arm C (GT2, Noncirrhotic)
Reporting group description: Ombitasvir (OBV)/paritaprevir (PTV)/ritonavir (r) (25/150/100) mg QD with sofosbuvir (SOF) (400 mg QD) and ribavirin (RBV; weight- based 1,000 mg or 1,200 mg daily divided BID) for 8 weeks.	
Reporting group title	Arm D (GT2, Noncirrhotic)
Reporting group description: Ombitasvir (OBV)/paritaprevir (PTV)/ritonavir (r) (25/150/100) mg QD with sofosbuvir (SOF) (400 mg QD) and ribavirin (RBV; weight-based 1,000 mg or 1,200 mg daily divided BID) for 6 weeks.	
Reporting group title	Arm E (GT3, Cirrhotic)
Reporting group description: Ombitasvir (OBV)/paritaprevir (PTV)/ritonavir (r) (25/150/100) mg QD with sofosbuvir (SOF) (400 mg QD) and ribavirin (RBV; weight-based 1,000 mg or 1,200 mg daily divided BID) for 12 weeks.	
Reporting group title	Arm F (GT3, Noncirrhotic)
Reporting group description: Ombitasvir (OBV)/paritaprevir (PTV)/ritonavir (r) (25/150/100) mg QD and Sofosbuvir (SOF) (400 mg QD) for 12 weeks.	

Primary: Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12)

End point title	Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12) ^[1]
End point description: SVR12 was defined as plasma hepatitis C virus ribonucleic acid (HCV RNA) level less than the lower limit of quantification [<LLOQ]) 12 weeks after the last dose of study drug.	
End point type	Primary
End point timeframe: 12 weeks after the last actual dose of study drug	

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Descriptive data are summarized for this end point per protocol.

End point values	Arm A (genotype [GT]3,	Arm B (GT3, noncirrhotic)	Arm C (GT2, Noncirrhotic)	Arm D (GT2, Noncirrhotic)
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	9	11	10	9
Units: percentage of participants				
number (confidence interval 95%)	100 (70.1 to 100)	90.9 (62.3 to 98.4)	90.0 (59.6 to 98.2)	44.4 (18.9 to 73.3)

End point values	Arm E (GT3, Cirrhotic)	Arm F (GT3, Noncirrhotic)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	21	10		
Units: percentage of participants				
number (confidence interval 95%)	100 (84.5 to 100)	100 (72.2 to 100)		

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Participants With On-treatment Virologic Failure

End point title	Percentage of Participants With On-treatment Virologic Failure
End point description:	On-treatment virologic failure was defined as confirmed increase of > 1 log(subscript)10(subscript) IU/mL above the lowest value post-baseline HCV RNA during treatment; confirmed HCV RNA ≥ LLOQ after HCV RNA < LLOQ during treatment, or HCV RNA ≥ LLOQ at end of treatment with at least 6 weeks of treatment for 12-week and 8-week treatment or at least 26 days of treatments for 6-week treatment.
End point type	Secondary
End point timeframe:	Up to Week 12

End point values	Arm A (genotype [GT]3,	Arm B (GT3, noncirrhotic)	Arm C (GT2, Noncirrhotic)	Arm D (GT2, Noncirrhotic)
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	9	11	10	9
Units: percentage of particip				
number (confidence interval 95%)	0 (0.0 to 29.9)	0 (0.0 to 25.9)	0 (0.0 to 27.8)	0 (0.0 to 29.9)

End point values	Arm E (GT3, Cirrhotic)	Arm F (GT3, Noncirrhotic)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	21	10		
Units: percentage of particip				
number (confidence interval 95%)	0 (0.0 to 15.5)	0 (0.0 to 27.8)		

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Participants With Post-treatment Relapse

End point title	Percentage of Participants With Post-treatment Relapse
-----------------	--

End point description:

Post-treatment relapse was defined as confirmed HCV RNA \geq LLOQ between the end of treatment and 12 weeks after the last dose of study drug among participants who completed treatment with HCV RNA levels $<$ LLOQ at the end of treatment.

End point type	Secondary
----------------	-----------

End point timeframe:

Up to 12 weeks after the last actual dose of active study drug

End point values	Arm A (genotype [GT]3,	Arm B (GT3, noncirrhotic)	Arm C (GT2, Noncirrhotic)	Arm D (GT2, Noncirrhotic)
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	9	10	10	9
Units: percentage of participants				
number (confidence interval 95%)	0 (0.0 to 29.9)	0 (0.0 to 27.8)	10.0 (1.8 to 40.4)	55.6 (26.7 to 81.1)

End point values	Arm E (GT3, Cirrhotic)	Arm F (GT3, Noncirrhotic)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	21	10		
Units: percentage of participants				
number (confidence interval 95%)	0 (0.0 to 15.5)	0 (0.0 to 27.8)		

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Treatment-emergent adverse events (TEAEs) and serious adverse events (TESAEs) were collected from first dose of study drug until 30 days after the last dose of study drug (up to 16 weeks).

Adverse event reporting additional description:

TEAEs and TESAEs are defined as any adverse event (AE) with an onset date that is after the first dose of study drug until 30 days after the last dose of study drug and were collected whether elicited or spontaneously reported by the participant.

Assessment type	Systematic
-----------------	------------

Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	20.0
--------------------	------

Reporting groups

Reporting group title	Arm A (genotype [GT]3, noncirrhotic)
-----------------------	--------------------------------------

Reporting group description:

Ombitasvir (OBV)/paritaprevir (PTV)/ritonavir (r) 25/150/100 mg once daily (QD) and sofosbuvir (SOF) 400 mg QD for 12 weeks

Reporting group title	Arm B (GT3, noncirrhotic)
-----------------------	---------------------------

Reporting group description:

Ombitasvir (OBV)/paritaprevir (PTV)/ritonavir (r) (25/150/100) mg QD with sofosbuvir (SOF) (400 mg QD) and ribavirin (RBV; weight-based 1,000 mg or 1,200 mg daily divided twice daily [BID]) for 12 weeks.

Reporting group title	Arm C (GT2, Noncirrhotic)
-----------------------	---------------------------

Reporting group description:

Ombitasvir (OBV)/paritaprevir (PTV)/ritonavir (r) (25/150/100) mg QD with sofosbuvir (SOF) (400 mg QD) and ribavirin (RBV; weight-based 1,000 mg or 1,200 mg daily divided BID) for 8 weeks

Reporting group title	Arm D (GT2, Noncirrhotic)
-----------------------	---------------------------

Reporting group description:

Ombitasvir (OBV)/paritaprevir (PTV)/ritonavir (r) (25/150/100) mg QD with sofosbuvir (SOF) (400 mg QD) and ribavirin (RBV; weight-based 1,000 mg or 1,200 mg daily divided BID) for 6 weeks

Reporting group title	E (GT3, Cirrhotic)
-----------------------	--------------------

Reporting group description:

Ombitasvir (OBV)/paritaprevir (PTV)/ritonavir (r) (25/150/100) mg QD with sofosbuvir (SOF) (400 mg QD) and ribavirin (RBV; weight-based 1,000 mg or 1,200 mg daily divided BID) for 12 weeks

Reporting group title	Arm F (GT3, Noncirrhotic)
-----------------------	---------------------------

Reporting group description:

Ombitasvir (OBV)/paritaprevir (PTV)/ritonavir (r) (25/150/100) mg QD and sofosbuvir (SOF) (400 mg QD) for 12 weeks

Serious adverse events	Arm A (genotype [GT]3, noncirrhotic)	Arm B (GT3, noncirrhotic)	Arm C (GT2, Noncirrhotic)
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 9 (0.00%)	0 / 11 (0.00%)	1 / 10 (10.00%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events	0	0	0
Blood and lymphatic system disorders			
Anaemia			

subjects affected / exposed	0 / 9 (0.00%)	0 / 11 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Pneumonia			
subjects affected / exposed	0 / 9 (0.00%)	0 / 11 (0.00%)	1 / 10 (10.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory tract infection viral			
subjects affected / exposed	0 / 9 (0.00%)	0 / 11 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	Arm D (GT2, Noncirrhotic)	E (GT3, Cirrhotic)	Arm F (GT3, Noncirrhotic)
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 9 (0.00%)	2 / 21 (9.52%)	0 / 10 (0.00%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events	0	0	0
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	0 / 9 (0.00%)	1 / 21 (4.76%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Pneumonia			
subjects affected / exposed	0 / 9 (0.00%)	0 / 21 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory tract infection viral			
subjects affected / exposed	0 / 9 (0.00%)	1 / 21 (4.76%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	Arm A (genotype [GT]3, noncirrhotic)	Arm B (GT3, noncirrhotic)	Arm C (GT2, Noncirrhotic)
Total subjects affected by non-serious adverse events subjects affected / exposed	8 / 9 (88.89%)	10 / 11 (90.91%)	10 / 10 (100.00%)
Vascular disorders			
Hot flush subjects affected / exposed	0 / 9 (0.00%)	0 / 11 (0.00%)	1 / 10 (10.00%)
occurrences (all)	0	0	1
Peripheral artery stenosis subjects affected / exposed	0 / 9 (0.00%)	0 / 11 (0.00%)	1 / 10 (10.00%)
occurrences (all)	0	0	1
General disorders and administration site conditions			
Chest pain subjects affected / exposed	1 / 9 (11.11%)	0 / 11 (0.00%)	0 / 10 (0.00%)
occurrences (all)	1	0	0
Energy increased subjects affected / exposed	0 / 9 (0.00%)	0 / 11 (0.00%)	1 / 10 (10.00%)
occurrences (all)	0	0	1
Fatigue subjects affected / exposed	3 / 9 (33.33%)	3 / 11 (27.27%)	3 / 10 (30.00%)
occurrences (all)	3	3	4
Feeling abnormal subjects affected / exposed	0 / 9 (0.00%)	0 / 11 (0.00%)	1 / 10 (10.00%)
occurrences (all)	0	0	1
Influenza like illness subjects affected / exposed	1 / 9 (11.11%)	1 / 11 (9.09%)	0 / 10 (0.00%)
occurrences (all)	1	1	0
Malaise subjects affected / exposed	0 / 9 (0.00%)	0 / 11 (0.00%)	1 / 10 (10.00%)
occurrences (all)	0	0	1
Oedema peripheral subjects affected / exposed	0 / 9 (0.00%)	0 / 11 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Pain subjects affected / exposed	0 / 9 (0.00%)	1 / 11 (9.09%)	0 / 10 (0.00%)
occurrences (all)	0	1	0
Reproductive system and breast disorders			

Benign prostatic hyperplasia subjects affected / exposed occurrences (all)	1 / 9 (11.11%) 1	0 / 11 (0.00%) 0	0 / 10 (0.00%) 0
Nipple pain subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 11 (0.00%) 0	0 / 10 (0.00%) 0
Respiratory, thoracic and mediastinal disorders			
cough subjects affected / exposed occurrences (all)	1 / 9 (11.11%) 1	0 / 11 (0.00%) 0	0 / 10 (0.00%) 0
Dyspnoea subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	3 / 11 (27.27%) 3	0 / 10 (0.00%) 0
Dyspnoea exertional subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 11 (0.00%) 0	0 / 10 (0.00%) 0
Epistaxis subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	1 / 11 (9.09%) 1	1 / 10 (10.00%) 1
Oropharyngeal pain subjects affected / exposed occurrences (all)	1 / 9 (11.11%) 1	0 / 11 (0.00%) 0	0 / 10 (0.00%) 0
Respiratory tract congestion subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 11 (0.00%) 0	0 / 10 (0.00%) 0
Upper respiratory tract congestion subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 11 (0.00%) 0	0 / 10 (0.00%) 0
Psychiatric disorders			
Agitation subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	1 / 11 (9.09%) 1	0 / 10 (0.00%) 0
Anxiety subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 11 (0.00%) 0	0 / 10 (0.00%) 0
depressed mood			

subjects affected / exposed	0 / 9 (0.00%)	0 / 11 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Depression			
subjects affected / exposed	0 / 9 (0.00%)	0 / 11 (0.00%)	1 / 10 (10.00%)
occurrences (all)	0	0	1
Disorientation			
subjects affected / exposed	0 / 9 (0.00%)	0 / 11 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Hallucination			
subjects affected / exposed	0 / 9 (0.00%)	0 / 11 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Insomnia			
subjects affected / exposed	1 / 9 (11.11%)	0 / 11 (0.00%)	2 / 10 (20.00%)
occurrences (all)	1	0	2
Irritability			
subjects affected / exposed	1 / 9 (11.11%)	0 / 11 (0.00%)	1 / 10 (10.00%)
occurrences (all)	1	0	1
Mood swings			
subjects affected / exposed	0 / 9 (0.00%)	0 / 11 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Sleep disorder			
subjects affected / exposed	0 / 9 (0.00%)	0 / 11 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Tearfulness			
subjects affected / exposed	0 / 9 (0.00%)	0 / 11 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Withdrawal syndrome			
subjects affected / exposed	0 / 9 (0.00%)	0 / 11 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Investigations			
Haemoglobin decreased			
subjects affected / exposed	0 / 9 (0.00%)	0 / 11 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
International normalised ratio decreased			

subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 11 (0.00%) 0	0 / 10 (0.00%) 0
Injury, poisoning and procedural complications			
Back injury			
subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 11 (0.00%) 0	0 / 10 (0.00%) 0
Contusion			
subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 11 (0.00%) 0	0 / 10 (0.00%) 0
Muscle strain			
subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 11 (0.00%) 0	1 / 10 (10.00%) 1
Cardiac disorders			
Palpitations			
subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 11 (0.00%) 0	0 / 10 (0.00%) 0
Nervous system disorders			
Disturbance in attention			
subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 11 (0.00%) 0	0 / 10 (0.00%) 0
Dizziness			
subjects affected / exposed occurrences (all)	1 / 9 (11.11%) 2	1 / 11 (9.09%) 1	1 / 10 (10.00%) 1
Dysgeusia			
subjects affected / exposed occurrences (all)	1 / 9 (11.11%) 1	0 / 11 (0.00%) 0	0 / 10 (0.00%) 0
Head discomfort			
subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	1 / 11 (9.09%) 1	0 / 10 (0.00%) 0
Headache			
subjects affected / exposed occurrences (all)	1 / 9 (11.11%) 1	2 / 11 (18.18%) 2	6 / 10 (60.00%) 8
Hypoaesthesia			
subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 11 (0.00%) 0	0 / 10 (0.00%) 0
Intercostal neuralgia			

subjects affected / exposed occurrences (all)	1 / 9 (11.11%) 1	0 / 11 (0.00%) 0	0 / 10 (0.00%) 0
Memory impairment subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	1 / 11 (9.09%) 1	0 / 10 (0.00%) 0
Paraesthesia subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 11 (0.00%) 0	0 / 10 (0.00%) 0
Poor quality sleep subjects affected / exposed occurrences (all)	1 / 9 (11.11%) 1	0 / 11 (0.00%) 0	0 / 10 (0.00%) 0
Blood and lymphatic system disorders Anaemia subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	1 / 11 (9.09%) 1	1 / 10 (10.00%) 1
Ear and labyrinth disorders Hypoacusis subjects affected / exposed occurrences (all)	1 / 9 (11.11%) 1	0 / 11 (0.00%) 0	0 / 10 (0.00%) 0
Eye disorders Dry eye subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 11 (0.00%) 0	1 / 10 (10.00%) 1
Vision blurred subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	1 / 11 (9.09%) 1	0 / 10 (0.00%) 0
Gastrointestinal disorders Abdominal discomfort subjects affected / exposed occurrences (all)	1 / 9 (11.11%) 1	0 / 11 (0.00%) 0	1 / 10 (10.00%) 1
Abdominal distension subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 11 (0.00%) 0	1 / 10 (10.00%) 1
abdominal pain upper subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 11 (0.00%) 0	1 / 10 (10.00%) 1
Constipation			

subjects affected / exposed	0 / 9 (0.00%)	1 / 11 (9.09%)	1 / 10 (10.00%)
occurrences (all)	0	1	1
Diarrhoea			
subjects affected / exposed	0 / 9 (0.00%)	1 / 11 (9.09%)	3 / 10 (30.00%)
occurrences (all)	0	1	3
Dry mouth			
subjects affected / exposed	1 / 9 (11.11%)	1 / 11 (9.09%)	0 / 10 (0.00%)
occurrences (all)	1	1	0
Dyspepsia			
subjects affected / exposed	0 / 9 (0.00%)	1 / 11 (9.09%)	1 / 10 (10.00%)
occurrences (all)	0	1	1
Flatulence			
subjects affected / exposed	0 / 9 (0.00%)	1 / 11 (9.09%)	0 / 10 (0.00%)
occurrences (all)	0	1	0
Gastrooesophageal reflux disease			
subjects affected / exposed	0 / 9 (0.00%)	0 / 11 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Mouth ulceration			
subjects affected / exposed	0 / 9 (0.00%)	1 / 11 (9.09%)	0 / 10 (0.00%)
occurrences (all)	0	1	0
Nausea			
subjects affected / exposed	0 / 9 (0.00%)	1 / 11 (9.09%)	3 / 10 (30.00%)
occurrences (all)	0	1	3
Stomatitis			
subjects affected / exposed	0 / 9 (0.00%)	0 / 11 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Vomiting			
subjects affected / exposed	1 / 9 (11.11%)	1 / 11 (9.09%)	0 / 10 (0.00%)
occurrences (all)	1	1	0
Skin and subcutaneous tissue disorders			
Dry skin			
subjects affected / exposed	0 / 9 (0.00%)	1 / 11 (9.09%)	1 / 10 (10.00%)
occurrences (all)	0	1	1
Eczema			
subjects affected / exposed	0 / 9 (0.00%)	1 / 11 (9.09%)	0 / 10 (0.00%)
occurrences (all)	0	1	0

Ingrowing nail			
subjects affected / exposed	0 / 9 (0.00%)	0 / 11 (0.00%)	2 / 10 (20.00%)
occurrences (all)	0	0	2
Night sweats			
subjects affected / exposed	0 / 9 (0.00%)	1 / 11 (9.09%)	0 / 10 (0.00%)
occurrences (all)	0	1	0
Pruritus			
subjects affected / exposed	1 / 9 (11.11%)	2 / 11 (18.18%)	0 / 10 (0.00%)
occurrences (all)	1	3	0
Pruritus allergic			
subjects affected / exposed	0 / 9 (0.00%)	1 / 11 (9.09%)	0 / 10 (0.00%)
occurrences (all)	0	1	0
Pruritus generalised			
subjects affected / exposed	0 / 9 (0.00%)	0 / 11 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Psoriasis			
subjects affected / exposed	0 / 9 (0.00%)	0 / 11 (0.00%)	1 / 10 (10.00%)
occurrences (all)	0	0	1
Rash			
subjects affected / exposed	0 / 9 (0.00%)	1 / 11 (9.09%)	0 / 10 (0.00%)
occurrences (all)	0	1	0
Rash erythematous			
subjects affected / exposed	0 / 9 (0.00%)	0 / 11 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Rash pruritic			
subjects affected / exposed	0 / 9 (0.00%)	0 / 11 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Skin odour abnormal			
subjects affected / exposed	0 / 9 (0.00%)	1 / 11 (9.09%)	0 / 10 (0.00%)
occurrences (all)	0	1	0
Skin ulcer			
subjects affected / exposed	0 / 9 (0.00%)	0 / 11 (0.00%)	1 / 10 (10.00%)
occurrences (all)	0	0	1
Renal and urinary disorders			
Chromaturia			

subjects affected / exposed	0 / 9 (0.00%)	0 / 11 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Micturition urgency			
subjects affected / exposed	0 / 9 (0.00%)	0 / 11 (0.00%)	1 / 10 (10.00%)
occurrences (all)	0	0	1
Pollakiuria			
subjects affected / exposed	0 / 9 (0.00%)	0 / 11 (0.00%)	1 / 10 (10.00%)
occurrences (all)	0	0	1
Urine odour abnormal			
subjects affected / exposed	0 / 9 (0.00%)	1 / 11 (9.09%)	0 / 10 (0.00%)
occurrences (all)	0	1	0
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	0 / 9 (0.00%)	0 / 11 (0.00%)	1 / 10 (10.00%)
occurrences (all)	0	0	1
Back pain			
subjects affected / exposed	0 / 9 (0.00%)	0 / 11 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Joint swelling			
subjects affected / exposed	1 / 9 (11.11%)	0 / 11 (0.00%)	0 / 10 (0.00%)
occurrences (all)	1	0	0
Muscle spasms			
subjects affected / exposed	0 / 9 (0.00%)	0 / 11 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal chest pain			
subjects affected / exposed	0 / 9 (0.00%)	0 / 11 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Myalgia			
subjects affected / exposed	0 / 9 (0.00%)	0 / 11 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Neck pain			
subjects affected / exposed	0 / 9 (0.00%)	1 / 11 (9.09%)	0 / 10 (0.00%)
occurrences (all)	0	1	0
Plantar fasciitis			

subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 11 (0.00%) 0	0 / 10 (0.00%) 0
Infections and infestations			
Ear infection			
subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 11 (0.00%) 0	0 / 10 (0.00%) 0
Gastroenteritis			
subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	1 / 11 (9.09%) 1	0 / 10 (0.00%) 0
Genital herpes			
subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 11 (0.00%) 0	1 / 10 (10.00%) 1
herpes zoster			
subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 11 (0.00%) 0	1 / 10 (10.00%) 1
Lower respiratory tract infection			
subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	1 / 11 (9.09%) 1	0 / 10 (0.00%) 0
Paronychia			
subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 11 (0.00%) 0	1 / 10 (10.00%) 1
Respiratory tract infection			
subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	1 / 11 (9.09%) 2	0 / 10 (0.00%) 0
Sinusitis			
subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 11 (0.00%) 0	0 / 10 (0.00%) 0
Upper respiratory tract infection			
subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 11 (0.00%) 0	4 / 10 (40.00%) 4
Urinary tract infection			
subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 11 (0.00%) 0	1 / 10 (10.00%) 1
Viral upper respiratory tract infection			
subjects affected / exposed occurrences (all)	1 / 9 (11.11%) 1	0 / 11 (0.00%) 0	0 / 10 (0.00%) 0

Metabolism and nutrition disorders			
Decreased appetite			
subjects affected / exposed	1 / 9 (11.11%)	0 / 11 (0.00%)	0 / 10 (0.00%)
occurrences (all)	1	0	0
Polydipsia			
subjects affected / exposed	0 / 9 (0.00%)	0 / 11 (0.00%)	1 / 10 (10.00%)
occurrences (all)	0	0	1

Non-serious adverse events	Arm D (GT2, Noncirrhotic)	E (GT3, Cirrhotic)	Arm F (GT3, Noncirrhotic)
Total subjects affected by non-serious adverse events			
subjects affected / exposed	9 / 9 (100.00%)	20 / 21 (95.24%)	8 / 10 (80.00%)
Vascular disorders			
Hot flush			
subjects affected / exposed	0 / 9 (0.00%)	0 / 21 (0.00%)	1 / 10 (10.00%)
occurrences (all)	0	0	1
Peripheral artery stenosis			
subjects affected / exposed	0 / 9 (0.00%)	0 / 21 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
General disorders and administration site conditions			
Chest pain			
subjects affected / exposed	0 / 9 (0.00%)	1 / 21 (4.76%)	0 / 10 (0.00%)
occurrences (all)	0	1	0
Energy increased			
subjects affected / exposed	0 / 9 (0.00%)	0 / 21 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Fatigue			
subjects affected / exposed	6 / 9 (66.67%)	10 / 21 (47.62%)	4 / 10 (40.00%)
occurrences (all)	9	13	4
Feeling abnormal			
subjects affected / exposed	0 / 9 (0.00%)	2 / 21 (9.52%)	2 / 10 (20.00%)
occurrences (all)	0	2	2
Influenza like illness			
subjects affected / exposed	0 / 9 (0.00%)	0 / 21 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Malaise			

subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 21 (0.00%) 0	0 / 10 (0.00%) 0
Oedema peripheral subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 21 (0.00%) 0	1 / 10 (10.00%) 1
Pain subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	1 / 21 (4.76%) 1	0 / 10 (0.00%) 0
Reproductive system and breast disorders			
Benign prostatic hyperplasia subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 21 (0.00%) 0	0 / 10 (0.00%) 0
Nipple pain subjects affected / exposed occurrences (all)	1 / 9 (11.11%) 1	0 / 21 (0.00%) 0	0 / 10 (0.00%) 0
Respiratory, thoracic and mediastinal disorders			
cough subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	1 / 21 (4.76%) 1	1 / 10 (10.00%) 1
Dyspnoea subjects affected / exposed occurrences (all)	1 / 9 (11.11%) 1	0 / 21 (0.00%) 0	0 / 10 (0.00%) 0
Dyspnoea exertional subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	2 / 21 (9.52%) 2	0 / 10 (0.00%) 0
Epistaxis subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 21 (0.00%) 0	0 / 10 (0.00%) 0
Oropharyngeal pain subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	1 / 21 (4.76%) 1	1 / 10 (10.00%) 1
Respiratory tract congestion subjects affected / exposed occurrences (all)	1 / 9 (11.11%) 1	0 / 21 (0.00%) 0	1 / 10 (10.00%) 1
Upper respiratory tract congestion			

subjects affected / exposed occurrences (all)	1 / 9 (11.11%) 1	0 / 21 (0.00%) 0	0 / 10 (0.00%) 0
Psychiatric disorders			
Agitation			
subjects affected / exposed occurrences (all)	1 / 9 (11.11%) 1	0 / 21 (0.00%) 0	0 / 10 (0.00%) 0
Anxiety			
subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	1 / 21 (4.76%) 2	1 / 10 (10.00%) 1
depressed mood			
subjects affected / exposed occurrences (all)	1 / 9 (11.11%) 3	0 / 21 (0.00%) 0	0 / 10 (0.00%) 0
Depression			
subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	1 / 21 (4.76%) 1	0 / 10 (0.00%) 0
Disorientation			
subjects affected / exposed occurrences (all)	1 / 9 (11.11%) 1	0 / 21 (0.00%) 0	0 / 10 (0.00%) 0
Hallucination			
subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 21 (0.00%) 0	1 / 10 (10.00%) 1
Insomnia			
subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	5 / 21 (23.81%) 5	1 / 10 (10.00%) 1
Irritability			
subjects affected / exposed occurrences (all)	1 / 9 (11.11%) 1	1 / 21 (4.76%) 1	1 / 10 (10.00%) 1
Mood swings			
subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 21 (0.00%) 0	1 / 10 (10.00%) 1
Sleep disorder			
subjects affected / exposed occurrences (all)	1 / 9 (11.11%) 1	1 / 21 (4.76%) 1	1 / 10 (10.00%) 1
Tearfulness			
subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 21 (0.00%) 0	1 / 10 (10.00%) 1

Withdrawal syndrome subjects affected / exposed occurrences (all)	1 / 9 (11.11%) 1	0 / 21 (0.00%) 0	0 / 10 (0.00%) 0
Investigations Haemoglobin decreased subjects affected / exposed occurrences (all)	1 / 9 (11.11%) 1	1 / 21 (4.76%) 1	0 / 10 (0.00%) 0
International normalised ratio decreased subjects affected / exposed occurrences (all)	1 / 9 (11.11%) 1	0 / 21 (0.00%) 0	0 / 10 (0.00%) 0
Injury, poisoning and procedural complications Back injury subjects affected / exposed occurrences (all)	1 / 9 (11.11%) 1	0 / 21 (0.00%) 0	0 / 10 (0.00%) 0
Contusion subjects affected / exposed occurrences (all)	1 / 9 (11.11%) 1	1 / 21 (4.76%) 1	1 / 10 (10.00%) 1
Muscle strain subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	1 / 21 (4.76%) 1	0 / 10 (0.00%) 0
Cardiac disorders Palpitations subjects affected / exposed occurrences (all)	1 / 9 (11.11%) 1	0 / 21 (0.00%) 0	0 / 10 (0.00%) 0
Nervous system disorders Disturbance in attention subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	1 / 21 (4.76%) 1	1 / 10 (10.00%) 1
Dizziness subjects affected / exposed occurrences (all)	2 / 9 (22.22%) 3	4 / 21 (19.05%) 4	2 / 10 (20.00%) 2
Dysgeusia subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 21 (0.00%) 0	1 / 10 (10.00%) 1
Head discomfort			

subjects affected / exposed	0 / 9 (0.00%)	0 / 21 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Headache			
subjects affected / exposed	3 / 9 (33.33%)	9 / 21 (42.86%)	2 / 10 (20.00%)
occurrences (all)	4	9	2
Hypoaesthesia			
subjects affected / exposed	0 / 9 (0.00%)	0 / 21 (0.00%)	1 / 10 (10.00%)
occurrences (all)	0	0	1
Intercostal neuralgia			
subjects affected / exposed	0 / 9 (0.00%)	0 / 21 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Memory impairment			
subjects affected / exposed	1 / 9 (11.11%)	0 / 21 (0.00%)	0 / 10 (0.00%)
occurrences (all)	1	0	0
Paraesthesia			
subjects affected / exposed	0 / 9 (0.00%)	0 / 21 (0.00%)	1 / 10 (10.00%)
occurrences (all)	0	0	1
Poor quality sleep			
subjects affected / exposed	1 / 9 (11.11%)	0 / 21 (0.00%)	0 / 10 (0.00%)
occurrences (all)	1	0	0
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	0 / 9 (0.00%)	0 / 21 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Ear and labyrinth disorders			
Hypacusis			
subjects affected / exposed	0 / 9 (0.00%)	0 / 21 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Eye disorders			
Dry eye			
subjects affected / exposed	0 / 9 (0.00%)	0 / 21 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Vision blurred			
subjects affected / exposed	0 / 9 (0.00%)	1 / 21 (4.76%)	1 / 10 (10.00%)
occurrences (all)	0	1	1
Gastrointestinal disorders			

Abdominal discomfort			
subjects affected / exposed	1 / 9 (11.11%)	1 / 21 (4.76%)	1 / 10 (10.00%)
occurrences (all)	1	1	1
Abdominal distension			
subjects affected / exposed	1 / 9 (11.11%)	1 / 21 (4.76%)	1 / 10 (10.00%)
occurrences (all)	1	1	1
abdominal pain upper			
subjects affected / exposed	0 / 9 (0.00%)	2 / 21 (9.52%)	0 / 10 (0.00%)
occurrences (all)	0	3	0
Constipation			
subjects affected / exposed	3 / 9 (33.33%)	0 / 21 (0.00%)	0 / 10 (0.00%)
occurrences (all)	3	0	0
Diarrhoea			
subjects affected / exposed	2 / 9 (22.22%)	2 / 21 (9.52%)	3 / 10 (30.00%)
occurrences (all)	2	3	3
Dry mouth			
subjects affected / exposed	0 / 9 (0.00%)	0 / 21 (0.00%)	1 / 10 (10.00%)
occurrences (all)	0	0	1
Dyspepsia			
subjects affected / exposed	3 / 9 (33.33%)	1 / 21 (4.76%)	0 / 10 (0.00%)
occurrences (all)	3	1	0
Flatulence			
subjects affected / exposed	0 / 9 (0.00%)	1 / 21 (4.76%)	0 / 10 (0.00%)
occurrences (all)	0	1	0
Gastrooesophageal reflux disease			
subjects affected / exposed	0 / 9 (0.00%)	0 / 21 (0.00%)	1 / 10 (10.00%)
occurrences (all)	0	0	1
Mouth ulceration			
subjects affected / exposed	0 / 9 (0.00%)	1 / 21 (4.76%)	0 / 10 (0.00%)
occurrences (all)	0	1	0
Nausea			
subjects affected / exposed	0 / 9 (0.00%)	6 / 21 (28.57%)	3 / 10 (30.00%)
occurrences (all)	0	10	3
Stomatitis			
subjects affected / exposed	1 / 9 (11.11%)	0 / 21 (0.00%)	0 / 10 (0.00%)
occurrences (all)	1	0	0

Vomiting			
subjects affected / exposed	0 / 9 (0.00%)	1 / 21 (4.76%)	0 / 10 (0.00%)
occurrences (all)	0	1	0
Skin and subcutaneous tissue disorders			
Dry skin			
subjects affected / exposed	0 / 9 (0.00%)	1 / 21 (4.76%)	1 / 10 (10.00%)
occurrences (all)	0	1	1
Eczema			
subjects affected / exposed	0 / 9 (0.00%)	1 / 21 (4.76%)	0 / 10 (0.00%)
occurrences (all)	0	1	0
Ingrowing nail			
subjects affected / exposed	0 / 9 (0.00%)	0 / 21 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Night sweats			
subjects affected / exposed	0 / 9 (0.00%)	0 / 21 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Pruritus			
subjects affected / exposed	2 / 9 (22.22%)	7 / 21 (33.33%)	1 / 10 (10.00%)
occurrences (all)	2	7	1
Pruritus allergic			
subjects affected / exposed	0 / 9 (0.00%)	0 / 21 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Pruritus generalised			
subjects affected / exposed	0 / 9 (0.00%)	2 / 21 (9.52%)	1 / 10 (10.00%)
occurrences (all)	0	2	1
Psoriasis			
subjects affected / exposed	0 / 9 (0.00%)	0 / 21 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Rash			
subjects affected / exposed	0 / 9 (0.00%)	4 / 21 (19.05%)	1 / 10 (10.00%)
occurrences (all)	0	4	1
Rash erythematous			
subjects affected / exposed	0 / 9 (0.00%)	2 / 21 (9.52%)	0 / 10 (0.00%)
occurrences (all)	0	2	0
Rash pruritic			

subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	3 / 21 (14.29%) 3	0 / 10 (0.00%) 0
Skin odour abnormal subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 21 (0.00%) 0	0 / 10 (0.00%) 0
Skin ulcer subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 21 (0.00%) 0	0 / 10 (0.00%) 0
Renal and urinary disorders Chromaturia subjects affected / exposed occurrences (all)	1 / 9 (11.11%) 1	1 / 21 (4.76%) 1	0 / 10 (0.00%) 0
Micturition urgency subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 21 (0.00%) 0	0 / 10 (0.00%) 0
Pollakiuria subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 21 (0.00%) 0	0 / 10 (0.00%) 0
Urine odour abnormal subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 21 (0.00%) 0	0 / 10 (0.00%) 0
Musculoskeletal and connective tissue disorders Arthralgia subjects affected / exposed occurrences (all)	1 / 9 (11.11%) 1	1 / 21 (4.76%) 1	1 / 10 (10.00%) 1
Back pain subjects affected / exposed occurrences (all)	2 / 9 (22.22%) 2	4 / 21 (19.05%) 4	0 / 10 (0.00%) 0
Joint swelling subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 21 (0.00%) 0	0 / 10 (0.00%) 0
Muscle spasms subjects affected / exposed occurrences (all)	2 / 9 (22.22%) 2	1 / 21 (4.76%) 1	0 / 10 (0.00%) 0
Musculoskeletal chest pain			

subjects affected / exposed	1 / 9 (11.11%)	0 / 21 (0.00%)	0 / 10 (0.00%)
occurrences (all)	1	0	0
Myalgia			
subjects affected / exposed	0 / 9 (0.00%)	3 / 21 (14.29%)	0 / 10 (0.00%)
occurrences (all)	0	4	0
Neck pain			
subjects affected / exposed	0 / 9 (0.00%)	0 / 21 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Plantar fasciitis			
subjects affected / exposed	0 / 9 (0.00%)	0 / 21 (0.00%)	1 / 10 (10.00%)
occurrences (all)	0	0	1
Infections and infestations			
Ear infection			
subjects affected / exposed	0 / 9 (0.00%)	2 / 21 (9.52%)	0 / 10 (0.00%)
occurrences (all)	0	2	0
Gastroenteritis			
subjects affected / exposed	0 / 9 (0.00%)	0 / 21 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Genital herpes			
subjects affected / exposed	0 / 9 (0.00%)	0 / 21 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
herpes zoster			
subjects affected / exposed	0 / 9 (0.00%)	0 / 21 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Lower respiratory tract infection			
subjects affected / exposed	0 / 9 (0.00%)	0 / 21 (0.00%)	1 / 10 (10.00%)
occurrences (all)	0	0	1
Paronychia			
subjects affected / exposed	0 / 9 (0.00%)	0 / 21 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Respiratory tract infection			
subjects affected / exposed	1 / 9 (11.11%)	0 / 21 (0.00%)	0 / 10 (0.00%)
occurrences (all)	2	0	0
Sinusitis			
subjects affected / exposed	1 / 9 (11.11%)	0 / 21 (0.00%)	0 / 10 (0.00%)
occurrences (all)	1	0	0

Upper respiratory tract infection subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	5 / 21 (23.81%) 5	1 / 10 (10.00%) 1
Urinary tract infection subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 21 (0.00%) 0	0 / 10 (0.00%) 0
Viral upper respiratory tract infection subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 21 (0.00%) 0	0 / 10 (0.00%) 0
Metabolism and nutrition disorders			
Decreased appetite subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	3 / 21 (14.29%) 3	2 / 10 (20.00%) 2
Polydipsia subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 21 (0.00%) 0	0 / 10 (0.00%) 0

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.

None reported.

Notes: